Reaching an independent vet founder for a PE-backed acquirer

• Founder & Clinical Director (target)

  Sole director and PSC

  Spoke on a BVA regional panel about staying independent in the face of corporate roll-ups. Has publicly pushed back on a previous unsolicited PE approach. Plain-spoken; distrusts jargon; engages with messages that show clinical operations knowledge, not financial structures.

• Practice Manager

  Operational owner

  Likely operational sponsor for any conversation that progresses past first contact. Background in human-side healthcare; quietly the most pragmatic voice in the room.

• Lead vet (hub site)

  Likely clinical successor

  Mentioned warmly in the founder’s public commentary. Not a recipient – but the autonomy frame should land for them as well as the founder.

Succession assessment: No formal succession plan filed. The founder is in their late 50s with no immediate exit signal – but the lead vet has been promoted into a clinical leadership posture, which is consistent with someone quietly thinking about what comes next.

• BVA regional panel – clinical autonomy: Spoke at length about consultation time being "the first thing to compress under corporate ownership". The clearest articulation of the problem from this founder publicly.
• Publicly turned down a previous PE approach: Referenced in a 2024 Vet Times comment. Shapes the tone any acquirer message can take.
• Shared out-of-hours model: Operationally pragmatic. Suggests an owner who builds adjacent partnerships rather than insisting on full vertical control.
• Lead vet promoted: Quiet succession signal. Not enough to imply intent to sell, but enough to support a "next-chapter" conversation that isn’t framed as an exit.

1. 1. The BVA autonomy talk

   The only legitimate hook. Reference the consultation-time line specifically – not just the topic.

2. 2. Shared out-of-hours model

   A point of pride. Acknowledging it shows you read past the company page.

3. 3. Sub-acquirer framing

   Position our client as the inverse of the pattern they already rejected. Don’t lead with the deal; lead with the question.

• Email-led, plain language

  They engage with messages that read as written, not assembled. LinkedIn is the wrong primary channel here.

• No financial vocabulary

  EBITDA, multiples, deal structure – all reads as the message they already binned. Substitute clinical operations language.

• Ask once, properly

  A second follow-up is appropriate. A third reads as pressure and undermines the entire frame.

• Name the rejected message

  Acknowledging that they’ve had unsolicited PE approaches before – and that we know – is honest and disarming.

• “In the BVA panel you said consultation time was the first thing to compress under corporate ownership – has that been your experience watching the chains operate locally?”
• “How did the shared out-of-hours model come together? It’s an unusual structure at this scale.”
• “Is the question of "what comes next" something you’ve started thinking about, or is it premature?”

• ⚠ Previous PE approach rejected publicly

  Anything that reads as the same pattern will be filed identically. The message has to look and sound categorically different.

• ⚠ No verified direct email

  Practice address is public; founder direct email is not. The message has to go via the practice channel; expect a clinic manager intercept on touch 1.

• ⚠ Local reputation

  Founders in this category often share notes through regional vet networks. The message has to be one we’d be comfortable having forwarded.

Messages aren’t drafted inside the dossier. Our strategic copywriters write every touchpoint from scratch using the research above; what follows is the light-touch direction we hand them.